Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H11N2O3.K |
| Molecular Weight | 222.2828 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CCC1(CC)C(=O)NC(=O)[N-]C1=O
InChI
InChIKey=FOQIEWZXCHZONC-UHFFFAOYSA-M
InChI=1S/C8H12N2O3.K/c1-3-8(4-2)5(11)9-7(13)10-6(8)12;/h3-4H2,1-2H3,(H2,9,10,11,12,13);/q;+1/p-1
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H11N2O3 |
| Molecular Weight | 183.1845 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3860 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
Other AEs: Coma... |
250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
Other AEs: Dizziness, Drug intoxication... Other AEs: Dizziness Sources: Drug intoxication Euphoric Tiredness |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Coma | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
|
| Dizziness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Drug intoxication | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Euphoric | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Tiredness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Immunoelectrophoresis of red blood cells performed on microcapillary chips. | 2002 Jul |
|
| Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. | 2002 Nov 4 |
|
| Biochemical mechanism of the effect of barbital on rifamycin B biosynthesis by Amycolatopsis mediterranei (M18 strain). | 2003 |
|
| Isolation and characterization of anticomplementary beta-glucans from the shoots of bamboo Phyllostachys edulis. | 2003 Jan |
|
| Complexation of phenolic guests by endo- and exo-hydrogen-bonded receptors. | 2003 Jul 21 |
|
| Rational design of the first closed coordination capsule with octahedral outer shape. | 2004 May 3 |
|
| Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. | 2005 Nov |
|
| Binding of small guest molecules to multivalent receptors. | 2005 Oct 14 |
|
| Selective self-organization of guest molecules in self-assembled molecular boxes. | 2005 Sep 14 |
|
| Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. | 2006 |
|
| Proximal visceral endoderm and extraembryonic ectoderm regulate the formation of primordial germ cell precursors. | 2007 Dec 20 |
|
| Modulation of the complement system by human beta-defensin 2. | 2007 Jan 10 |
|
| Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. | 2007 Mar 16 |
|
| The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. | 2008 Dec |
|
| Surviving mousepox infection requires the complement system. | 2008 Dec |
|
| Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. | 2009 Apr |
|
| Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. | 2009 Feb |
|
| Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. | 2010 Jun 7 |
|
| Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells. | 2010 Mar 16 |
|
| Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. | 2010 May 27 |
|
| Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. | 2010 Oct 20 |
Patents
Sample Use Guides
It was reported the action of sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), which plays a significant role in energy homeostasis in the muscles. The activity of CK underwent a rapid decrease when the concentration of sodium barbital was increased to 8 mmol/L, and the residual activity was about 35% of then active CK. The activity of CK dropped slowly until it was almost 0 when the concentration of sodium barbital was increased to 125 mmol/L. These results indicated that sodium barbital might function as an inhibitor of CK.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:02:36 GMT 2023
by
admin
on
Sat Dec 16 19:02:36 GMT 2023
|
| Record UNII |
QZ6VB88G2Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
QZ6VB88G2Z
Created by
admin on Sat Dec 16 19:02:36 GMT 2023 , Edited by admin on Sat Dec 16 19:02:36 GMT 2023
|
PRIMARY | |||
|
4388-77-6
Created by
admin on Sat Dec 16 19:02:36 GMT 2023 , Edited by admin on Sat Dec 16 19:02:36 GMT 2023
|
PRIMARY | |||
|
23686184
Created by
admin on Sat Dec 16 19:02:36 GMT 2023 , Edited by admin on Sat Dec 16 19:02:36 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|